Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 11Dermatologic 2Tumor-Agnostic 1Other solid neoplasm 1Head & Neck 1Gynecologic 1Gastrointestinal 1CNS 1Breast 1

Conditions

Melanoma 1Glioblastoma 1Carcinoma, Medullary 1

Interventions

Temozolomide 623Radiotherapy 411Bevacizumab 257Magnetic Resonance Spectroscopy 227Cyclophosphamide 179Radiosurgery 163Carboplatin 160Etoposide 132Radiation 129Vincristine 115Irinotecan 115Cisplatin 103Filgrastim 100Specimen Handling 90Nivolumab 88pembrolizumab 84Surgical Procedures, Operative 83Lomustine 82Topotecan 73Doxorubicin 61Melphalan 59Carmustine 57Radiotherapy, Intensity-Modulated 56sargramostim 53Isotretinoin 53Peripheral Blood Stem Cell Transplantation 52Granulocyte Colony-Stimulating Factor 51Chemotherapy, Adjuvant 51Blood Specimen Collection 51Erlotinib Hydrochloride 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
rovalpituzumab tesirine × CNS × Clear all
NCT02709889 2020-10-19

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

AbbVie

Phase 1/2 Terminated
200 enrolled 21 charts
CNSDermatologic

Glioblastoma, Melanoma, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡